Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Published:2021-08-18 Issue:17 Volume:10 Page:5748-5756
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Ferrarotto Renata¹^ORCID,Anderson Ian²,Medgyasszay Balazs³,García‐Campelo Maria Rosario⁴,Edenfield William⁵,Feinstein Trevor M.⁶,Johnson Jennifer M.⁷,Kalmadi Sujith⁸,Lammers Philip E.⁹,Sanchez‐Hernandez Alfredo¹⁰,Pritchett Yili¹¹,Morris Shannon R.¹¹,Malik Rajesh K.¹¹,Csőszi Tibor¹²

Affiliation:

1. University of Texas MD Anderson Cancer Center Houston TX USA

2. St Joseph Heritage Healthcare Santa Rosa CA USA

3. Veszprém County Lung Medicine Institute Veszprém Hungary

4. University Hospital A Coruña A Coruña Spain

5. Prisma Health Cancer Institute Greenville SC USA

6. Piedmont Cancer Institute Atlanta GA USA

7. Thomas Jefferson University Hospital Philadelphia PA USA

8. Ironwood Cancer & Research Center Chandler AZ USA

9. Baptist Cancer Center Memphis TN USA

10. Hospital Provincial de Castellon Castelló Spain

11. G1 Therapeutics, Inc. Research Triangle Park NC USA

12. Hetenyi Geza Korhaz Szolnok Hungary

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4089

Reference29 articles.

1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

2. Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

3. Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)

4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

5. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?;Supportive Care in Cancer;2024-08-31

2. Lost at SCLC: a review of potential platinum sensitizers;Cancer and Metastasis Reviews;2024-08-23

3. A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of metastatic small-cell lung cancer;Medicinal Chemistry Research;2024-07-26

4. Exploring the Mechanism of Shen Qi Gui Oral Liquid against Chemotherapy-Induced Myelosuppression in Cancer Patients Based on Network Pharmacology and Molecular Docking;Combinatorial Chemistry & High Throughput Screening;2024-07-09

5. Exploration of the Active Component and Mechanisms of Shengyu Decoction Against Myelosuppression Using Network Pharmacology and in vitro Experimental Validation;Drug Design, Development and Therapy;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3